>> HPV-16 SEROPREVALENCE IN A POPULATION-BASED SUB-SAMPLE OF PUERTO RICAN ADULTS
11:45 AM - 12:00 PM
1Cancer Control and Population Sciences Program, University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico; 2Biostatistics and Epidemiology Department, Graduate School of Public Health, University of Puerto Rico, San Juan, Puerto Rico; 3Chronic Viral Diseases Branch, Centers for Disease Control and Prevention.
Background: HPV-16 is the most common HPV type detected in most regions of the world. Although serologic testing is considered to be a valid measure of cumulative HPV exposure, worldwide data on HPV seroprevalence is limited and data for Puerto Rico (PR) is non-existent. This study estimated the prevalence and correlates of seropositivity to HPV-16 Viral Like Particles (VLPs) in adults in PR.
Methods: Serum from 450 consecutive participants of the 1,654 adults (21-64 years) participating in a PR island-wide population-based study of hepatitis in 2005-2008 were included in this analysis. Seropositivity to HPV-16 was determined by a direct ELISA against HPV 16 L1-VLPs. Cut-off value was determined using parallel line analysis in reference to the HPV 16 International Standard serum. Socio-demographic, health and lifestyle characteristics were elicited by interviewer-administered and self-administered questionnaire (using an ACASI system). Logistic regression models were used to estimate the magnitude of association between HPV-16 seropositivity and different co-factors.
Results: Prevalence of seropositivity to HPV-16 was 11.3%; 5.6% in men and 15.8% in women (p=0.001). Prevalence was significantly (p=0.04) higher in persons aged 21-39 years (14.7%) than those aged 40-64 (8.5%). Ever smokers (OR: 2.09, 95% CI=1.10-3.96) and persons with >= 3 lifetime sexual partners (OR: 1.98, 95% CI=1.02-3.84) were more likely to be HPV-16 seropositive, after adjusting for age and sex. No significant differences were observed by education, income or age of sexual initiation (p>0.05).
Conclusions: HPV-16 seropositivity for this sub-sample of adults in PR (11.3%) is similar to that reported in the US (10.4%) for NHANES 2003-2004 participants, although different assays were used in these studies. Correlates of seropositivity are also consistent with previous studies. The need to further understand the burden of HPV and HPV-related malignancies in PR is underscored; additional studies of younger ages are needed to evaluate age of exposure.